We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QGEN icon
76
Qiagen
QGEN
$8.49B
$2.78M 0.24%
+72,463
New +$2.67M
CHRS icon
77
Coherus Oncology
CHRS
$216M
$2.77M 0.24%
197,835
+47,835
+32% +$685K
QTNT
78
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.57M 0.22%
7,995
+5,245
+191% +$1.23M
TNDM icon
79
Tandem Diabetes Care
TNDM
$1.17B
$2.51M 0.21%
+114,006
New +$1.4M
LGND icon
80
Ligand Pharmaceuticals
LGND
$6.08B
$2.5M 0.21%
19,348
-7,342
-28% -$819K
EGRX
81
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.5M 0.21%
33,000
– –
AGIO icon
82
Agios Pharmaceuticals
AGIO
$2.36B
$2.43M 0.21%
28,811
-11,489
-29% -$1M
JNJ icon
83
Johnson & Johnson
JNJ
$609B
$2.43M 0.21%
20,000
– –
QTRX icon
84
Quanterix
QTRX
$182M
$2.38M 0.2%
165,480
+81,680
+97% +$1.41M
TEVA icon
85
Teva Pharmaceuticals
TEVA
$37.3B
$2.19M 0.19%
90,000
– –
ICPT
86
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.07M 0.18%
24,648
-7,252
-23% -$531K
NVRO
87
DELISTED
NEVRO CORP.
NVRO
$2.06M 0.18%
25,798
+15,098
+141% +$1.25M
BLUE
88
DELISTED
bluebird bio
BLUE
$2.02M 0.17%
996
-31
-3% -$70.7K
HCA icon
89
HCA Healthcare
HCA
$82.3B
$1.95M 0.17%
19,000
-2,300
-11% -$233K
PEN icon
90
Penumbra
PEN
$12.5B
$1.94M 0.17%
14,027
-2,773
-17% -$395K
SAGE
91
DELISTED
Sage Therapeutics
SAGE
$1.89M 0.16%
12,100
-350
-3% -$54.9K
ONC
92
BeOne Medicines Ltd
ONC
$32.4B
$1.77M 0.15%
11,500
-29,150
-72% -$5.2M
INSP icon
93
Inspire Medical Systems
INSP
$1.46B
$1.71M 0.15%
+47,953
New +$1.55M
RGNX icon
94
Regenxbio
RGNX
$534M
$1.71M 0.15%
+23,800
New +$1.14M
NKTR icon
95
Nektar Therapeutics
NKTR
$2.31B
$1.69M 0.14%
2,300
-67
-3% -$77.3K
ANGO icon
96
AngioDynamics
ANGO
$558M
$1.68M 0.14%
75,700
-26,000
-26% -$531K
AGN
97
DELISTED
Allergan plc
AGN
$1.67M 0.14%
10,000
-3,000
-23% -$482K
MCK icon
98
McKesson
MCK
$98.5B
$1.58M 0.13%
11,850
-1,950
-14% -$285K
PTLA
99
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.57M 0.13%
41,500
-1,200
-3% -$45.9K
PODD icon
100
Insulet
PODD
$11.4B
$1.54M 0.13%
18,000
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.